Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
Hello, and welcome to Day 1 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, we have Intellia Therapeutics with us and representing Intellia is Ian Karp, SVP of IR and Corporate Communications. Ian, would you like to start off with some opening remarks, then we'll jump into Q&A.
Sure. And thanks so much for having us. Yes, Intellia for those that are a bit new to Intellia, we're one of the leading full spectrum genome managing companies, which really means 3 things. So we're focused in 3 core areas, which is building out a deep gene editing capability and a toolbox that we can use for therapeutic purposes, and we then deploy those tools both on the in vivo and ex vivo side of human therapeutics. So on the in vivo side, we're actually delivering the CRISPR machinery to make those edits typically for -- to address disease-causing proteins or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |